Becker's Healthcare November 21, 2025
Eli Lilly plans to launch a direct-to-employer model for its GLP-1 medications in early 2026 in a move aimed at giving companies more flexibility in designing obesity management benefits for their employees.
The model will include three components: flexible benefit design options for obesity care, a dedicated pharmacy network with transparent pricing, and customized obesity management programs through independent third parties, according to a Nov. 21 news release.
The announcement comes as GLP-1 pricing and access continue to...
Today's Sponsors
Today's Sponsor